NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong antitumor activity as single agent and in combination in preclinical models.

C. Perrera, M. Pulici, P. Banfi, N. Avanzi, D. Carenzi, D. Casero, A. Ciavolella, L. Gianellini, F. Gasparri, G. Saturno, B. Valsasina, E. Ardini, A. Montagnoli, A. Galvani, A. Isacchi
AACR Annual Meeting 2023; 2023 April 14-19; Orlando, FL.

–Abstract 1615
Cancer Res (2023) 83 (7_Supplement)